In­di­an man­u­fac­tur­ing play­er Ju­bi­lant poach­es top No­var­tis BD ex­ec to run their new biotech start­up in Yard­ley, PA

The In­di­an drug man­u­fac­tur­er and de­vel­op­er Ju­bi­lant Life Sci­ences is ramp­ing up a new biotech com­pa­ny in Yard­ley, PA. And they’ve raid­ed a long­time BD ex­ec from No­var­tis to lead the “se­mi-vir­tu­al” biotech as they hatch new deals to build the pipeline.

Ju­bi­lant spread word to­day that Syed Kaz­mi is the new CEO at Ju­bi­lant Ther­a­peu­tics, which has been giv­en a slate of pre­clin­i­cal drugs for its pipeline. Those drugs in­clude a dual epi­ge­net­ic in­hibitor of LSD1/HDAC6 for acute myeloid leukemia, a small mol­e­cule PD-L1 ther­a­py with “com­pa­ra­ble ef­fi­ca­cy to large mol­e­cules and low­er side ef­fects,” and a small mol­e­cule PAD4 in­hibitor with po­ten­tial to treat mul­ti­ple au­to-im­mune dis­or­ders along with a PRMT5 in­hibitor for lym­phoma.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER